Plasma and cerebrospinal fluid neurofilament light concentrations reflect neuronal damage in systemic lupus Erythematosus

被引:9
|
作者
Zervides, Kristoffer A. [1 ,2 ]
Janelidze, Shorena [3 ]
Nystedt, Jessika [2 ]
Gullstrand, Birgitta [1 ]
Nilsson, Petra [2 ]
Sundgren, Pia C. C. [4 ,5 ]
Bengtsson, Anders A. A. [1 ]
Hansson, Oskar [3 ,6 ]
Jonsen, Andreas [1 ]
机构
[1] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Rheumatol, Lund, Sweden
[2] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Neurol, Lund, Sweden
[3] Lund Univ, Dept Clin Sci, Clin Memory Res Unit, Malmo, Sweden
[4] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Diagnost Radiol, Lund, Sweden
[5] Lund Univ, BioImaging Ctr, Lund, Sweden
[6] Skane Univ Hosp, Memory Clin, Malmo, Sweden
基金
瑞典研究理事会;
关键词
Neurofilament light; Systemic lupus erythematosus; Neuropsychiatric; Biomarker; Plasma; Cerebrospinal fluid; MRI; Cognitive dysfunction; Organ damage; INDEX; POPULATION; VALIDATION; COMPLEMENT; VALIDITY; CRITERIA;
D O I
10.1186/s12883-022-02998-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BackgroundNeuronal damage in systemic lupus erythematosus (SLE) is common, but the extent and mechanisms are unclear. Neurofilament light (NfL) concentrations rise in plasma and cerebrospinal fluid (CSF) during neuronal damage in various neurological disorders. In this cross-sectional study, plasma and CSF concentrations of NfL were explored as a marker of neuronal damage in SLE.MethodsSeventy-two consecutive SLE out-patients and 26 healthy controls, all female, aged < 55 years, underwent magnetic resonance imaging (MRI) and neurocognitive testing. NfL concentrations in plasma from all individuals and in CSF from 32 patients were measured with single-molecule array technology. Patients were assessed by a rheumatologist and neurologist to define neuropsychiatric involvement (NPSLE) according to three attribution models: SLICC A, SLICC B and ACR.ResultsPlasma and CSF NfL concentrations correlated strongly (r = 0.72, p < 0.001). Both NPSLE and non-NPSLE patients in all attribution models had higher plasma NfL concentrations compared with healthy controls (log-NfL, pg/ml, mean (SD); healthy controls (0.71 (0.17)); SLICC A model: NPSLE (0.87 (0.13), p = 0.003), non-NPSLE (0.83 (0.18), p = 0.005); SLICC B model: NPSLE (0.87 (0.14), p = 0.001), non-NPSLE (0.83 (0.18), p = 0.008); ACR model: NPSLE (0.86 (0.16), p < 0.001), non-NPSLE (0.81 (0.17), p = 0.044)). Plasma and CSF NfL concentrations did not differ between NPSLE and non-NPSLE patients. Higher plasma NfL concentrations correlated with larger CSF volumes on MRI (r = 0.34, p = 0.005), and was associated with poorer cognitive performance in the domains of simple attention, psychomotor speed and verbal memory. SLICC/ACR-Damage Index >= 1 was independently associated with higher plasma NfL concentrations (beta = 0.074, p = 0.038). Higher plasma creatinine concentrations, anti-dsDNA-positivity, low complement C3 levels, or a history of renal involvement were associated with higher plasma NfL concentrations (beta = 0.003, p = 0.009; beta = 0.072, p = 0.031; beta = 0.077, p = 0.027; beta = 0.069, p = 0.047, respectively).ConclusionsHigher plasma NfL concentrations in NPSLE and non-NPSLE patients may indicate a higher degree of neuronal damage in SLE in general, corresponding to cognitive impairment and organ damage development. Furthermore, our results may indicate a higher degree of neuronal breakdown in patients with active SLE, also without overt clinical symptoms. NfL may serve as an indicator of neuronal damage in SLE in further studies.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Filtration of cerebrospinal fluid for acute demyelinating neuropathy in systemic lupus erythematosus
    Stahl, HD
    Kalischewski, P
    Orda, C
    Baum, P
    Grahmann, F
    Emmrich, F
    CLINICAL RHEUMATOLOGY, 2000, 19 (01) : 61 - 63
  • [22] Filtration of cerebrospinal fluid for acute demyelinating neuropathy in systemic lupus erythematosus
    Stahl H.-D.
    Kalischewski P.
    Orda C.
    Baum P.
    Grahmann F.
    Emmrich F.
    Clinical Rheumatology, 2000, 19 (1) : 61 - 63
  • [23] Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus
    Ruiz-Arruza, Ioana
    Ugarte, Amaia
    Cabezas-Rodriguez, Ivan
    Medina, Jose-Alejandro
    Moran, Miguel-Angel
    Ruiz-Irastorza, Guillermo
    RHEUMATOLOGY, 2014, 53 (08) : 1470 - 1476
  • [24] Biomarkers for systemic lupus erythematosus - a focus on organ damage
    Ding, Huihua
    Shen, Yiwei
    Hong, Soon-Min
    Xiang, Chunyan
    Shen, Nan
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2024, 20 (01) : 39 - 58
  • [25] Identifying damage clusters in patients with systemic lupus erythematosus
    Ahn, Ga Young
    Lee, Jiyoung
    Won, Soyoung
    Ha, Eunji
    Kim, Hyoungyoung
    Nam, Bora
    Kim, Ji Soong
    Kang, Juyeon
    Kim, Jae-Hoon
    Song, Gwan Gyu
    Kim, Kwangwoo
    Bae, Sang-Cheol
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2020, 23 (01) : 84 - 91
  • [26] Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer's disease
    Andersson, Emelie
    Janelidze, Shorena
    Lampinen, Bjorn
    Nilsson, Markus
    Leuzy, Antoine
    Stomrud, Erik
    Blennow, Kaj
    Zetterberg, Henrik
    Hansson, Oskar
    NEUROBIOLOGY OF AGING, 2020, 95 : 143 - 153
  • [27] Plasma osteopontin as a marker for future organ damage in pediatric systemic lupus erythematosus
    Ornella J Rullo
    Jennifer MP Woo
    Alice DC Hoftman
    Miriam F Parsa
    Gil Amarilyo
    Deborah K McCurdy
    Betty P Tsao
    Pediatric Rheumatology, 10 (Suppl 1)
  • [28] Trajectory of Damage Accrual in Systemic Lupus Erythematosus Based on Ethnicity and Socioeconomic Factors
    Kallas, Romy
    Li, Jessica
    Goldman, Daniel W.
    Magder, Laurence S.
    Petri, Michelle
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (11) : 1229 - 1235
  • [29] Association of serum neurofilament light chain levels and neuropsychiatric manifestations in systemic lupus erythematosus
    Engel, Sinah
    Boedecker, Simone
    Marczynski, Paul
    Bittner, Stefan
    Steffen, Falk
    Weinmann, Arndt
    Schwarting, Andreas
    Zipp, Frauke
    Weinmann-Menke, Julia
    Luessi, Felix
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2021, 14
  • [30] Proteomic Analysis of Cerebrospinal Fluid: A Search for Biomarkers of Neuropsychiatric Systemic Lupus Erythematosus
    Pedroza-Diaz, Johanna
    Lujan Chavarria, Tania Paola
    Munoz Vahos, Carlos Horacio
    Hernandez Ramirez, Diego Francisco
    Olivares-Martinez, Elizabeth
    Vasquez, Gloria
    Llorente, Luis
    Fragoso-Loyo, Hilda
    Rothlisberger, Sarah
    Ortiz Reyes, Blanca Lucia
    CURRENT PROTEOMICS, 2019, 16 (02) : 110 - 118